Fimlab Laboratories has selected Aiforia Technologies as the provider for breast and prostate cancer diagnostics solutions. Fimlab is Finland’s largest healthcare laboratory company, owned by the wellbeing services counties of Pirkanmaa, Central Finland, Kanta-Häme, Ostrobothnia, and Päijät-Häme.
Earlier this year, Aiforia announced a framework agreement in which it was selected as one of the suppliers of AI solutions for Fimlab to support pathology diagnostics. Three best suppliers were chosen for AI models for nine applications and a development platform for AI models. Aiforia was qualified as one of the suppliers for eight applications and the development platform.
The AI solutions for breast and prostate cancer, representing three applications, are the first order for Aiforia within the multi-year framework agreement. The value of this first order for Aiforia is approximately €300,000 for the first year.
“We are extremely excited to officially kickstart this cooperation. Fimlab is a true pioneer in Finland in adopting AI solutions to support diagnostics in pathology. It is an honour to be part of this progressive step in our home country,” says Jukka Tapaninen, CEO of Aiforia.